CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
PALO ALTO, Calif., February 21, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that 11 abstracts on clinical and preclinical studies have been accepted for presentation at the of Cardiology (ACC) 57th Annual Scientific Session, which will be held in Chicago, IL on March 29 - April 1, 2008.
Ranexa(R) (ranolazine extended-release tablets):
Ranolazine Suppresses Ectopic Activity in Isolated Rat Left Atrial Appendage; Poster; Sunday, March 30, 2008, 10:00 a.m. CST
Ranolazine Attenuates Palmitoyl-L-Carnitine Induced Ventricular Diastolic Dysfunction; Poster; Sunday, March 30, 2008, 11:00 a.m. CST
Ranolazine's Mechanism of Action for Reducing Myocardial Infarct Size is Independent of Changes in Coronary Collateral Blood Flow; Poster, Sunday, March 30, 2008, 11:00 a.m. CST
Ranolazine Prevents Ischemia-Induced ST Segment Changes and Left Ventricular Mechanical Dysfunction in Rabbits; Poster, Sunday, March 30, 2008, 11:00 a.m. CST
Ranolazine Increases Glucose Stimulated Insulin Secretion in Rats; Poster, Monday, March 31, 2008, 10:00 a.m. CST
Ranolazine Shortens Repolarization and Improves Myocardial Relaxation in Patients with Type-3 Long QT Syndrome; Poster, Monday, March 31, 2008, 10:00 a.m. CST
Chronic Kidney Disease, Cardiovascular Outcomes, and Treatment Disparities Following Non-ST Elevation Myocardial Infarction; Poster, Monday, March 31, 2008, 3:00 p.m. CST
Effects of Ranolazine on Disease-Specific Health Status and Quality of Life: Results from the MERLIN-TIMI 36 Randomized Trial; Poster, Monday, March 31, 2008, 3:00 p.m. CST
Myeloperoxidase Levels Associated with Risk of Cardiovascular Death and Heart Failure after Non-ST Elevation Acute Coronary Syndrome; Poster, Monday, March 31, 2008, 3:00 p.m. CST
Efficacy and Safety of Ranolazine in Chronic Angina: Observations from the Randomized, Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster, Tuesday, April 1, 2008, 11:00 a.m. CST
Heart Rate Response to Adenosine and Regadenoson in Diabetes Mellitus: A Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1, 2008, 11:30 a.m. CST
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed for potential treatment of cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward- looking statements.
CONTACT: Investor and Media Contact: John Bluth, Executive Director,Corporate Communications & Investor Relations of CV Therapeutics, Inc.,+1-650-384-8850
Web site: http://www.cvt.com/
Ticker Symbol: (NASDAQ-NMS:CVTX)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2008